Literature DB >> 22699956

High rate of non-eligibility: methodological factors impacting on recruitment for a multicentre, double-blind study of paediatric patients with major depressive disorder.

L Bliznak1, R Berg, A Häge, R W Dittmann.   

Abstract

INTRODUCTION: This report describes difficulties encountered when attempting to recruit children and adolescents with major depression for a recent international double-blind, placebo-controlled trial (www.clinicaltrials.gov Nr. NCT00849901).
METHODS: Over a 14-month period, children and adolescents with depressive symptoms were pre-screened for their eligibility for inclusion.
RESULTS: 85 patients (age 7-17 years) were considered. Of these, only one was enrolled. The main reasons for non-eligibility were: failure to meet the baseline severity criterion on the primary outcome scale (clinical global impression-severity; 32.1% of the patients); requirement for immediate hospitalisation (15.4%); or the presence of an exclusionary comorbid psychiatric disorder (19.1%). DISCUSSION: The recruitment of paediatric patients with major depression was primarily limited by various inclusion and exclusion criteria. Slow recruitment of small patient samples may impact strongly on the representativeness and generalisability of research findings, and thus on analyses in evidence-based medicine and on the development and recommendations of treatment guidelines. This may impact in turn on the feasibility of the clinical development and registration process of new compounds in paediatric psychopharmacology and beyond. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2012        PMID: 22699956     DOI: 10.1055/s-0032-1314806

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  5 in total

1.  Defining the hidden evidence in autism research. Forty per cent of rigorously designed clinical trials remain unpublished - a cross-sectional analysis.

Authors:  Konstantin Mechler; Georg F Hoffmann; Ralf W Dittmann; Markus Ries
Journal:  Int J Methods Psychiatr Res       Date:  2016-11-09       Impact factor: 4.035

2.  Barriers for recruitment to treatment of youths with co-occurring substance use disorders and depression.

Authors:  Yifrah Kaminer; Grace Chan; Rebecca Burke
Journal:  Am J Addict       Date:  2022-06-28

3.  New generation antidepressants for depression in children and adolescents: a network meta-analysis.

Authors:  Sarah E Hetrick; Joanne E McKenzie; Alan P Bailey; Vartika Sharma; Carl I Moller; Paul B Badcock; Georgina R Cox; Sally N Merry; Nicholas Meader
Journal:  Cochrane Database Syst Rev       Date:  2021-05-24

4.  "Include me if you can"-reasons for low enrollment of pediatric patients in a psychopharmacological trial.

Authors:  Larissa Niemeyer; Konstantin Mechler; Jan Buitelaar; Sarah Durston; Bram Gooskens; Bob Oranje; Tobias Banaschewski; Ralf W Dittmann; Alexander Häge
Journal:  Trials       Date:  2021-03-01       Impact factor: 2.279

5.  Memantine as treatment for compulsivity in child and adolescent psychiatry: Descriptive findings from an incompleted randomized, double-blind, placebo-controlled trial.

Authors:  Larissa Niemeyer; Konstantin Mechler; Ralf W Dittmann; Tobias Banaschewski; Jan Buitelaar; Sarah Durston; Alexander Häge
Journal:  Contemp Clin Trials Commun       Date:  2022-08-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.